Cambridge Equities, LP → ImmunityBio, Inc. IBRX

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 21/100

Passive Schedule 13G filer baseline
Elevated short days-to-cover (7.2 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

0 buys · 1 sales · 0 awards/exercises

Issuer Cluster

8 13D/G filings on this issuer

7 other filings besides this one

Filer Track Record

8 filings by this filer

7 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 7.15

122,945,839 shares short · -0.9% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-06-24	Simon Barry J.	director	Sale	25,000	$7.88	$197K

Other 13D/G Filings on ImmunityBio, Inc.

Filed	Form	Filer	Stake	Shares
2026-08-06	SCHEDULE 13D/A	Cambridge Equities, LP	64.80%	261,705,814	view →
2024-01-04	SC	Cambridge Equities, LP	—	—	view →
2022-12-07	SC	Cambridge Equities, LP	—	—	view →
2021-03-12	SC	Cambridge Equities, LP	—	—	view →
2020-12-21	SC	Cambridge Equities, LP	—	—	view →
2020-06-29	SC	Cambridge Equities, LP	—	—	view →
2019-04-01	SC	Cambridge Equities, LP	—	—	view →

Other Filings by Cambridge Equities, LP

Filed	Form	Issuer	Stake	Shares
2026-08-06	SCHEDULE 13D/A	ImmunityBio, Inc.	64.80%	261,705,814	view →
2024-01-04	SC	ImmunityBio, Inc. IBRX	—	—	view →
2022-12-07	SC	ImmunityBio, Inc. IBRX	—	—	view →
2021-03-12	SC	ImmunityBio, Inc. IBRX	—	—	view →
2020-12-21	SC	NantKwest, Inc. IBRX	—	—	view →
2020-06-29	SC	NantKwest, Inc. IBRX	—	—	view →
2019-04-01	SC	NantKwest, Inc. IBRX	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →